Clinical Trials
58
Active:44
Completed:12
Trial Phases
2 Phases
Phase 1:47
Phase 3:9
Drug Approvals
2
FDA:2
Clinical Trials
Distribution across different clinical trial phases (56 trials with phase data)• Click on a phase to view related trials
Phase 1
47 (83.9%)Phase 3
9 (16.1%)Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
Phase 3
Completed
- Conditions
- Severe Hemophilia A
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bioverativ Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02502149
- Locations
- 🇳🇿
Research Site, Hamilton, New Zealand
Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease
Completed
- Conditions
- HealthySickle Cell Disease
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bioverativ Therapeutics Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02447627
- Locations
- 🇺🇸
Research Site, Detroit, Michigan, United States
Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
Terminated
- Conditions
- Hemophilia AHemophilia B
- Interventions
- Biological: rFVIIIFcBiological: rFIXFcDrug: non-Fc FVIII replacement productsDrug: non-Fc FIX replacement products
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bioverativ Therapeutics Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02392156
- Locations
- 🇺🇸
Research Site, East Lansing, Michigan, United States
Pharmacokinetics of rFVIIIFc at Two Vial Strengths
Phase 1
Completed
- Conditions
- Severe Hemophilia A
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bioverativ Therapeutics Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02083965
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
Phase 3
Completed
- Conditions
- Hemophilia A
- Interventions
- Drug: BIIB031 (rFVIIIFc)Drug: FVIII (PK subgroup only)
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bioverativ Therapeutics Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01458106
- Locations
- 🇬🇧
Research Site, London, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
No news found